American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris,Herbert A. Fritsche,Robert G. Mennel,Larry Norton,Peter M. Ravdin,Sheila E. Taube,Mark R. Somerfield,Daniel F. Hayes,Robert C. Bast +8 more
TLDR
Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and not all applications for these markers were supported, however.Abstract:
Purpose To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. Methods For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee’s literature review focused attention on available systematic reviews and metaanalyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Recommendations and Conclusionsread more
Citations
More filters
Journal ArticleDOI
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Gyorffy,András Lánczky,Aron Charles Eklund,Carsten Denkert,Jan Budczies,Qiyuan Li,Zoltan Szallasi,Zoltan Szallasi +7 more
TL;DR: An online tool to draw survival plots, which can be used to assess the relevance of the expression levels of various genes on the clinical outcome both in untreated and treated breast cancer patients, and which validated the capability of microarrays to determine estrogen receptor status in 1,231 patients.
Journal ArticleDOI
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett,Torsten O. Nielsen,Roger A'Hern,John M. S. Bartlett,R. Charles Coombes,Jack Cuzick,Matthew J. Ellis,N. Lynn Henry,Judith Hugh,Tracy Lively,Lisa M. McShane,Soon Paik,Frédérique Penault-Llorca,Ljudmila Prudkin,Meredith M. Regan,Janine Salter,Christos Sotiriou,Ian E. Smith,Giuseppe Viale,Jo Anne Zujewski,Daniel F. Hayes +20 more
TL;DR: Comprehensive recommendations on preanalytical and analytical assessment, and interpretation and scoring of Ki67 were formulated based on current evidence, geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice.
Journal ArticleDOI
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,Della F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,Matthew P. Goetz,John A. Olson,John A. Olson,Tracy Lively,Sunil Badve,Thomas J. Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Soonmyung Paik,William C. Wood,Peter M. Ravdin,Maccon M. Keane,Henry L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,Jeffery L. Berenberg,Jeffrey Abrams,George W. Sledge +31 more
TL;DR: In this paper, the authors performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer.
Journal ArticleDOI
Gene-expression signatures in breast cancer.
Christos Sotiriou,Lajos Pusztai +1 more
TL;DR: The results of gene-expression studies that hold the most promise to accelerate the transition between empirical and molecular medicine are summarized.
Journal ArticleDOI
Detection, clinical relevance and specific biological properties of disseminating tumour cells
TL;DR: The evidence that disseminating tumour cells have a variety of uses for understanding tumour biology and improving cancer treatment is reviewed.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie,Charles M. Perou,Robert Tibshirani,Turid Aas,Stephanie Geisler,Hilde Johnsen,Trevor Hastie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,T. Thorsen,Hanne Quist,John C. Matese,Patrick O. Brown,David Botstein,Per Eystein Lønning,Anne Lise Børresen-Dale +16 more
TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van't Veer,Hongyue Dai,Marc J. van de Vijver,Yudong D. He,Augustinus A. M. Hart,Mao Mao,Hans Peterse,Karin van der Kooy,Matthew J. Marton,Anke T. Witteveen,George J. Schreiber,Ron M. Kerkhoven,Christopher J. Roberts,Peter S. Linsley,René Bernards,Stephen H. Friend +15 more
TL;DR: DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.